In recent times, the stock markets have returned to a semblance of normalcy and many stocks have managed to generate significant gains during that time. One of the stocks to have made a strong move over the course of the past two weeks is that of Pressure Biosciences Inc (OTCMKTS:PBIO), which has rallied by as much as 15%.
In such a situation, it could be worthwhile for investors to take a closer look at the company, its operations, and the recent developments around it. Pressure BioSciences is involved in the development and sale of pressure-based solutions to the global life sciences industry. It should be noted that the company also works with other industries.
The company has also developed a patented technology named pressure cycling technology and at this point in time, Pressure BioSciences working towards the development of more PCT-based products. Earlier on in June, the company made a major announcement regarding an order received by its merger partner SkinScience Labs.
It was accounted that SkinScience had received an order for its premium hand sanitizers worth $3.5 million. It is a significant development for Pressure as well considering the fact that it had announced plans to acquire SkinScience back in April this year. The coronavirus pandemic has sent the demand for hand sanitizers through the roof and as a matter of fact, many companies have entered the fray in order to claim a slice of the lucrative market.
According to a report from Radiant Insights from back in 2019, the global market for sanitizers is expected to be worth $5.5 billion in 2024. That being said, it must be noted that the coronavirus pandemic might see a paradigm shift for the demand in sanitizers and actually see much higher growth. The merger between the Pressure and SkinScience could unlock considerable value if the latter’s hand sanitizers can get more traction.
There have been other important developments surrounding Pressure BioSciences as well in recent times and it could be important for investors to keep abreast of those. At the end of June, the company announced that it signed a global co-marketing deal with the German company Leica Microsystems CMS GmbH. It is a major new alliance for Pressure and is expected to be a major boost to the global cancer research ecosystem as a whole.
The two entities are going to co-market a novel enabling platform that combines Pressure BioScience’s PCT and Leica Laser Microdissection (LMD) System. It is not really a surprise that the alliance between the two is being called a historic one. The stock may have got a boost, by the way, these two recent events. Investors could consider adding the stock on to their watch lists.
Neither PSN nor its owners, members, officers, directors, partners, consultants, nor anyone involved in the publication of this website, is a registered investment adviser or broker-dealer or associated person with a registered investment adviser or broker-dealer and none of the foregoing make any recommendation that the purchase or sale of securities of any company profiled in the PSN website is suitable or advisable for any person or that an investment or transaction in such securities will be profitable. The information contained in the PSN website is not intended to be, and shall not constitute, an offer to sell nor the solicitation of any offer to buy any security. The information presented in the PSN website is provided for informational purposes only and is not to be treated as advice or a recommendation to make any specific investment. Please consult with an independent investment adviser and qualified investment professional before making an investment decision.